MENU
+Compare
AKBLF
Stock ticker: OTC
AS OF
Jan 8 closing price
Price
$20.30
Change
-$2.05 (-9.17%)
Capitalization
4.61B

AKBLF stock forecast, quote, news & analysis

AKBLF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for AKBLF with price predictions
Jan 08, 2025

AKBLF sees MACD Histogram just turned negative

AKBLF saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on January 08, 2025. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 18 instances where the indicator turned negative. In of the 18 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on January 08, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on AKBLF as a result. In of 21 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Aroon Indicator for AKBLF entered a downward trend on December 20, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AKBLF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.398) is normal, around the industry mean (14.744). P/E Ratio (42.007) is within average values for comparable stocks, (88.252). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.853). AKBLF has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (6.169) is also within normal values, averaging (264.079).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
published Dividends

AKBLF paid dividends on March 20, 2017

Alk Abello AS AKBLF Stock Dividends
А dividend of $100.00 per share was paid with a record date of March 20, 2017, and an ex-dividend date of March 16, 2017. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Nektar Therapeutics (NASDAQ:NKTR).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.37B. The market cap for tickers in the group ranges from 151 to 368.92B. NONOF holds the highest valuation in this group at 368.92B. The lowest valued company is MYMX at 151.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -1%. For the same Industry, the average monthly price growth was 3%, and the average quarterly price growth was -2%. MMIRF experienced the highest price growth at 498%, while SEELQ experienced the biggest fall at -95%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -30%. For the same stocks of the Industry, the average monthly volume growth was -51% and the average quarterly volume growth was 97%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 63
SMR Rating: 94
Profit Risk Rating: 94
Seasonality Score: 14 (-100 ... +100)
View a ticker or compare two or three
AKBLF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
Boge Alle 6-8
Phone
+45 45747576
Employees
2824
Web
https://www.alk.net